Esperion Therapeutics

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Endpoints
Daiichi Sankyo
Esperion Therapeutics
Flag link:
What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug
What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug
Motley Fool
Esperion Therapeutics
bempedoic acid
cholesterol
Flag link:
A new drug lowers cholesterol. Can it spoil a multibillion-dollar market?
A new drug lowers cholesterol. Can it spoil a multibillion-dollar market?
Stat
Esperion Therapeutics
bempedoic acid
LDL cholesterol
Flag link:
Highly anticipated trial results expected soon could move all three of these biotechs
Highly anticipated trial results expected soon could move all three of these biotechs
Motley Fool
Sangamo Therapeutics
Esperion Therapeutics
Loxo Oncology
SB-913
bempedoic acid
LOXO-292
Flag link:
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
Forbes
Esperion Therapeutics
bempedoic acid
statins
Zetia
Merck
cholesterol
Flag link:
Esperion's LDL med aces a third pivotal trial
Esperion's LDL med aces a third pivotal trial
Fierce Biotech
Esperion Therapeutics
clinical trials
bempedoic acid
ASCVD
Flag link:
Esperion tumbles as patient deaths weigh on cholesterol drug
Esperion tumbles as patient deaths weigh on cholesterol drug
Biopharma Dive
Esperion Therapeutics
clinical trials
bempedoic acid
Flag link:
Esperion bolsters cholesterol drug with new combo data
Esperion bolsters cholesterol drug with new combo data
Biopharma Dive
Esperion Therapeutics
bempedoic acid
cholesterol
Flag link:
Esperion's cholesterol drug succeeds in late-stage study
Esperion's cholesterol drug succeeds in late-stage study
Reuters
Esperion Therapeutics
clinical trials
bempedoic acid
cholesterol
Flag link:
5 Biotech Stocks That Could Be Bought Out in 2018
5 Biotech Stocks That Could Be Bought Out in 2018
Yahoo/Motley Fool
biotech stocks
Portola Pharmaceuticals
Tesaro
Bluebird Bio
Esperion Therapeutics
GlycoMimetics
Flag link:
3 Small Biotech Stocks Being Run by Proven Winners
3 Small Biotech Stocks Being Run by Proven Winners
Motley Fool
biotech
Axovant
Esperion Therapeutics
Aurinia Pharmaceuticals
Richard Glickman
David Hung
Roger Newton
Flag link:
3 Best Biotech Stocks During Trump's First 100 Days
3 Best Biotech Stocks During Trump's First 100 Days
Motley Fool
biotech stocks
Donald Trump
Esperion Therapeutics
Aurinia Pharmaceuticals
TG Therapeutics
Flag link:
Could Pfizer Buy Esperion Therapeutics?
Could Pfizer Buy Esperion Therapeutics?
Motley Fool
Pfizer
Esperion Therapeutics
M&A
bococizumab
Flag link:
Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug
Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug
Forbes
Esperion Therapeutics
FDA
bempadoic acid
heart disease
heart attacks
Flag link:
Amgen Blew It…For Medicines Co., Esperion Too
Amgen Blew It…For Medicines Co., Esperion Too
Barron's
Amgen
Medicines Company
Esperion Therapeutics
Repatha
inclisiran
Flag link:
Biotechs Breaking Out On Drug Development News
Biotechs Breaking Out On Drug Development News
Forbes
Bluebird Bio
Esperion Therapeutics
Amicus Therapeutics
Kite Pharma
Flag link:
Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill
Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill
TheStreet.com
Esperion Therapeutics
LDL-C
ETC-1002
Flag link:
Amgen's Acquisition Of Dezima And CETP Drug Like Pfizer's '03 Buy Of Esperion. Will History Repeat?
Amgen's Acquisition Of Dezima And CETP Drug Like Pfizer's '03 Buy Of Esperion. Will History Repeat?
Forbes
Amgen
Dezima
CETP inhibitors
Pfizer
M&A
Esperion Therapeutics
Flag link:
Esperion surges after FDA offers a shot at quick approval for LDL-lowering drug
Esperion surges after FDA offers a shot at quick approval for LDL-lowering drug
Fierce Biotech
FDA
Esperion Therapeutics
LDL cholesterol
ETC-1002
Flag link:
Why Regeneron’s Approval is Bad News For Esperion Therapeutics
Why Regeneron’s Approval is Bad News For Esperion Therapeutics
Barron's
Regeneron
Esperion Therapeutics
Sanofi
Praluent
Amgen
Repatha
ETC-1002
Flag link:

Pages